Live Chat

CFD:er är komplexa instrument som innebär hög risk att du förlorar pengar snabbt på grund av hävstången. 74% av icke-professionella investerares konton förlorar pengar när de handlar med CFD:er hos den här leverantören. Du bör överväga om du förstår hur CFD:er fungerar och om du har råd att ta den höga risken att förlora dina pengar.

Close

Affär Vir Biotechnology VIR

VirBiotechnology realtidsdiagram

Instrumentfundament

Weekly Search
Weekly
Daily
Datum Stäng Förändring Förändring (%) Öppna Hög Låg

Senaste nyheter

Frances Wang 2024 Dec 19, 16:00

Analyst revises Amazon stock forecast following major 'moonshot' initiative

Stocks
Frances Wang 2024 Dec 19, 16:00

Stock market today: 3 bullish stocks that J.P. Morgan Just Upgraded

Stocks
Frances Wang 2024 Dec 19, 16:00

Bitcoin news today: Jerome Powell Says Fed Won’t Hold Bitcoin

Cryptocurrencies
Frances Wang 2024 Dec 19, 16:00

Gold performance and prediction: how high could gold price go?

Commodities
UK GDP
Dyogenes Diniz 2024 Dec 19, 16:00

Week ahead: Last full week of 2024 in the Financial Markets

Forex Indices
Frances Wang 2024 Dec 18, 16:00

Stock market today: Nasdaq Hits Record Highs as Tesla Achieves New Peaks

Stocks
Frances Wang 2024 Dec 18, 16:00

Dow Jones tumbles 1,100 points: why did the stock market go down today?

Stocks
Frances Wang 2024 Dec 18, 16:00

Super Micro Shares Drop 8% Following Nasdaq 100 Removal

Stocks

Info

Spread

0.07

Spread (%)

0.9576 %

Hävstångseffekt

1:5

Köp till dagslåneränta

-0.0597 %

Sälj till dagslåneränta

-0.0292 %

Valuta

USD

Handelstider

Marknaderna är stängda

Måndag

14:31 - 20:59

Tisdag

14:31-17:59

Torsdag

14:31-20:59

Fredag

14:31-20:59

Analys och statistik

Öppna

---

Föregående stängning

---

52 veckors högsta/lägsta

--- – ---

Marknadsvärde

1010864832

Utelöpande aktier

137720000

Rapportdatum (nästa)

0000-00-00

Utd-procent

Datum efter utdelning

Förväntad framtida årlig utdelningsprocent

0

Förväntad framtida årlig direktavkastning

0

Vinst per aktie

-3.93

Läs mer om detta instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Läs mer om detta instrument

Tillgång
Sälj
Köp
Förändring (%)
Relaterade instrument
Trustpilot
Live Chat